{
    "clinical_study": {
        "@rank": "168278", 
        "arm_group": {
            "arm_group_label": "Gabapentin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a pilot study to evaluate the tolerability and effects of maintenance gabapentin\n      therapy on the rate of premature birth in women who have had preterm labor."
        }, 
        "brief_title": "Maintenance Gabapentin to Prolong Pregnancy.", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Preterm Labor, Premature Birth", 
        "condition_browse": {
            "mesh_term": [
                "Obstetric Labor, Premature", 
                "Premature Birth"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Eligibility Criteria:\n\n          1. Healthy 18-45 year old female with singleton pregnancy, 20-34 weeks gestation,\n             without ruptured membranes.\n\n          2. Preterm labor defined as regular uterine contractions of at least 6/hour for \u2265 1 hour\n             with \u2265 1cm of cervical dilation or \u2264 2.5cm cervical length or any documented cervical\n             change from the initial pelvic exam.\n\n          3. Cervical dilation not more than 4cm.\n\n          4. Initiation of a tocolytic agent (e.g. magnesium sulfate, nifedipine, indomethacin)\n             within the previous 72 hours.\n\n          5. Pregnancy not conceived through in-vitro fertilization (IVF) due to the known higher\n             rates of congenital defects associated with this procedure.30\n\n          6. No placenta praevia or abruptio placentae or cervical cerclage.\n\n          7. No intra-uterine growth restriction or non-reassuring fetal status.\n\n          8. No known serious fetal malformations.\n\n          9. No chorioamnionitis or medical/psychiatric/substance abuse comorbidity that may\n             complicate the pregnancy or interfere with the subject's ability to comply with study\n             procedures in the opinion of Dr. Guttuso or the subject's obstetrician.\n\n         10. No history of suicide attempt.  No suicidal thoughts over past 6 months.\n\n         11. Not currently receiving gabapentin, pregabalin, progesterone or a known teratogenic\n             medication and no known allergy to gabapentin therapy."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02056899", 
            "org_study_id": "423140-2"
        }, 
        "intervention": {
            "arm_group_label": "Gabapentin", 
            "intervention_name": "Gabapentin", 
            "intervention_type": "Drug", 
            "other_name": "Neurontin"
        }, 
        "intervention_browse": {
            "mesh_term": "Gabapentin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Preterm labor, premature birth, gabapentin", 
        "lastchanged_date": "February 5, 2014", 
        "location": {
            "contact": {
                "last_name": "Thomas Guttuso, Jr., MD"
            }, 
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14214"
                }, 
                "name": "University at Buffalo"
            }, 
            "investigator": {
                "last_name": "Thomas Guttuso, Jr., MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effect of Maintenance Gabapentin Therapy on the Rate of Premature Birth in Women With Preterm Labor After Receiving Tocolysis.", 
        "overall_contact": {
            "email": "tguttuso@buffalo.edu", 
            "last_name": "Thomas Guttuso, Jr., MD", 
            "phone": "716-829-5454"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rate of premature birth (before 37 weeks gestation)", 
            "safety_issue": "No", 
            "time_frame": "At delivery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02056899"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University at Buffalo", 
            "investigator_full_name": "Thomas Guttuso", 
            "investigator_title": "Associate Professor of Neurology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University at Buffalo", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University at Buffalo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}